ANN ARBOR—Genomenon Inc., the Ann Arbor-based genomics research information provider, has announced a partnership with Google to make the company’s genomic mutation data available on Google Cloud platform.
Genomenon’s Cited Variants Reference (CVR) data will be a public dataset available in BigQuery, Google Cloud’s big data and machine learning data warehouse, for use in genomic applications.
The Cited Variants Reference is generated from Genomenon’s Mastermind genomic database, which contains one of the most comprehensive indexes of genomic literature in the world. With more than 4.1 million genomic variants found in medical literature, each variant is annotated with a citation count based on the number of scientific publications mentioning the variant, along with a link into the Mastermind Genomic Search Engine to view full search results for those articles. The CVR is designed to help clinicians and researchers prioritize and scale their genomic interpretation.
The CVR dataset is also useful for researchers exploring novel, unpublished variants across patient cohort genomic data sets by looking for variants with little or no evidence in the medical literature.
The Mastermind Genomic Search Engine reads the titles and abstracts of more than 30 million scientific medical papers published in PubMed. The full text of articles found to have genomic information is then indexed to develop a comprehensive view of the genomic literature. To date, Mastermind has indexed the text of over 6.2 million genomic publications and found over 4.1 million genomic variants. The genomic variants and article citation counts for each variant are now available on Google Cloud platform.
Used by hundreds of diagnostic labs around the world, Mastermind accelerates genomic interpretation by providing unique insight into genomic relationships found in the full text of millions of scientific articles.
Pharmaceutical researchers license the Mastermind database for a comprehensive genomic landscape associated with any given disease—to identify and prioritize genomic biomarkers for drug discovery and clinical trial targets. For more information, visit http://www.genomenon.com.